Schizophrenia News

Otsuka and Lundbeck have announced FDA acceptance of a supplemental new drug application for Rexulti for the treatment of schizophrenia in adolescents.

An implantable loop recorder feasibly and acceptably monitored arrythmias among patients taking psychotropic medication, according to results of a cohort study in a research letter published in JAMA Psychiatry.

Monthly extended-release risperidone demonstrated efficacy for improving various schizophrenia symptoms, according to study results published in Journal of Clinical Psychiatry.

Healio Psychiatry has compiled a list of its five most-viewed stories in September.

Premorbid factors including obstetric complications, personal psychiatric background and IQ may help predict which patients are at increased risk for early-onset psychosis, according to study results.

The transmission of psychiatric disorders to first-degree relatives is higher among those related to patients with bipolar disorders, according to data published in The Journal of Clinical Psychiatry.

People with severe mental illness in an Israeli public psychiatric hospital opted to be vaccinated against COVID-19 based on their opinion of the vaccine, not distress level, researchers wrote in a study published in Journal of Psychiatric Research.

Antipsychotic treatment did not increase risk for mortality among adults with serious mental illness diagnosed with COVID-19 infection, according to study results in a research letter published in JAMA Psychiatry.

While poor sleep quality indicated better social functioning, poor sleep and social functioning were associated with increased psychotic-like experiences in college students, according to a study in Journal of Psychiatric Research.

Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone extended-release injectable suspension for subcutaneous use, a schizophrenia treatment.